Literature DB >> 24722062

HOXB13 G84E-related familial prostate cancers: a clinical, histologic, and molecular survey.

Steven C Smith1, Nallasivam Palanisamy, Kimberly A Zuhlke, Anna M Johnson, Javed Siddiqui, Arul M Chinnaiyan, Lakshmi P Kunju, Kathleen A Cooney, Scott A Tomlins.   

Abstract

Recent genetic epidemiologic studies identified a germline mutation in the homeobox transcription factor, HOXB13 G84E, which is associated with markedly increased risk for prostate cancer, particularly early-onset hereditary prostate cancer. The histomorphologic and molecular features of cancers arising in such carriers have not been studied. Here, we reviewed prostatectomy specimens from 23 HOXB13 G84E mutation carriers, mapping the total cancer burden by anatomically distinct cancer focus and evaluating morphologic features. We also assessed basic molecular subtypes for all cancer foci (ERG/SPINK1 status) by dual immunohistochemistry staining on full sections. The cohort showed a median age of 58 years, a median serum PSA level of 5.7 ng/mL, and a median of 6 cancer foci (range, 1 to 14) per case. Of evaluable cases, dominant foci were Gleason score 6 in 23%, 3+4=7 in 41%, 4+3=7 in 23%, and ≥8 in 14%; biochemical recurrence was observed in 1 case over a median of 36 months follow-up. Histologic review found a high prevalence of cases showing cancers with a spectrum of features previously described with pseudohyperplastic carcinomas, with 45% of cases showing a dominant focus with such features. Molecular subtyping revealed a strikingly low prevalence of ERG cancer with increased prevalence of SPINK1 cancer (dominant focus ERG 17%, SPINK1 26%, ERG/SPINK1 52%, single ERG/SPINK1 focus 4%). One ERG/SPINK1 dominant focus showed aberrant p63 immunophenotype. In summary, HOXB13 G84E variant-related prostate cancers show frequent pseudohyperplastic-type features and markedly low prevalence of ERG cancers relative to unselected cases and, especially, to early-onset cohorts. These findings suggest that novel molecular pathways may drive disease in HOXB13 G84E carriers.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24722062      PMCID: PMC3988475          DOI: 10.1097/PAS.0000000000000090

Source DB:  PubMed          Journal:  Am J Surg Pathol        ISSN: 0147-5185            Impact factor:   6.394


  60 in total

1.  Pseudohyperplastic prostatic adenocarcinoma on needle biopsy and simple prostatectomy.

Authors:  A W Levi; J I Epstein
Journal:  Am J Surg Pathol       Date:  2000-08       Impact factor: 6.394

2.  Posterior Hox gene expression and differential androgen regulation in the developing and adult rat prostate lobes.

Authors:  Liwei Huang; Yongbing Pu; David Hepps; David Danielpour; Gail S Prins
Journal:  Endocrinology       Date:  2006-11-30       Impact factor: 4.736

3.  HOXB13 G84E mutation in Finland: population-based analysis of prostate, breast, and colorectal cancer risk.

Authors:  Virpi H Laitinen; Tiina Wahlfors; Leena Saaristo; Tommi Rantapero; Liisa M Pelttari; Outi Kilpivaara; Satu-Leena Laasanen; Anne Kallioniemi; Heli Nevanlinna; Lauri Aaltonen; Robert L Vessella; Anssi Auvinen; Tapio Visakorpi; Teuvo L J Tammela; Johanna Schleutker
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-01-04       Impact factor: 4.254

4.  Detection of ERG gene rearrangements and PTEN deletions in unsuspected prostate cancer of the transition zone.

Authors:  Shuhong Liu; Maisa Yoshimoto; Kiril Trpkov; Qiuli Duan; Matthew Firszt; Jacques Corcos; Jeremy A Squire; Tarek A Bismar
Journal:  Cancer Biol Ther       Date:  2011-03-15       Impact factor: 4.742

5.  Antibody-based detection of ERG rearrangement-positive prostate cancer.

Authors:  Kyung Park; Scott A Tomlins; Kumaran M Mudaliar; Ya-Lin Chiu; Raquel Esgueva; Rohit Mehra; Khalid Suleman; Sooryanarayana Varambally; John C Brenner; Theresa MacDonald; Abhishek Srivastava; Ashutosh K Tewari; Ubaradka Sathyanarayana; Dea Nagy; Gary Pestano; Lakshmi P Kunju; Francesca Demichelis; Arul M Chinnaiyan; Mark A Rubin
Journal:  Neoplasia       Date:  2010-07       Impact factor: 5.715

6.  Confirmation of the HOXB13 G84E germline mutation in familial prostate cancer.

Authors:  Joan P Breyer; T Grant Avritt; Kate M McReynolds; William D Dupont; Jeffrey R Smith
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2012-06-19       Impact factor: 4.254

7.  ERG rearrangement in small cell prostatic and lung cancer.

Authors:  Veit J Scheble; Martin Braun; Theresia Wilbertz; Ann-Cathrin Stiedl; Karen Petersen; David Schilling; Markus Reischl; Gerhard Seitz; Falko Fend; Glen Kristiansen; Sven Perner
Journal:  Histopathology       Date:  2010-06       Impact factor: 5.087

8.  SPINK1 expression is tightly linked to 6q15- and 5q21-deleted ERG-fusion negative prostate cancers but unrelated to PSA recurrence.

Authors:  Katharina Grupp; Franz Diebel; Hüseyin Sirma; Ronald Simon; Karin Breitmeyer; Stefan Steurer; Claudia Hube-Magg; Kristina Prien; Taher Pham; Philipp Weigand; Uwe Michl; Hans Heinzer; Martina Kluth; Sarah Minner; Maria Christina Tsourlakis; Jakob R Izbicki; Guido Sauter; Thorsten Schlomm; Waldemar Wilczak
Journal:  Prostate       Date:  2013-07-10       Impact factor: 4.104

9.  The role of SPINK1 in ETS rearrangement-negative prostate cancers.

Authors:  Scott A Tomlins; Daniel R Rhodes; Jianjun Yu; Sooryanarayana Varambally; Rohit Mehra; Sven Perner; Francesca Demichelis; Beth E Helgeson; Bharathi Laxman; David S Morris; Qi Cao; Xuhong Cao; Ove Andrén; Katja Fall; Laura Johnson; John T Wei; Rajal B Shah; Hikmat Al-Ahmadie; James A Eastham; Scott E Eggener; Samson W Fine; Kristina Hotakainen; Ulf-Håkan Stenman; Alex Tsodikov; William L Gerald; Hans Lilja; Victor E Reuter; Phillip W Kantoff; Peter T Scardino; Mark A Rubin; Anders S Bjartell; Arul M Chinnaiyan
Journal:  Cancer Cell       Date:  2008-06       Impact factor: 31.743

10.  Novel dual-color immunohistochemical methods for detecting ERG-PTEN and ERG-SPINK1 status in prostate carcinoma.

Authors:  Ritu Bhalla; Lakshmi P Kunju; Scott A Tomlins; Kelly Christopherson; Connie Cortez; Shannon Carskadon; Javed Siddiqui; Kyung Park; Juan Miguel Mosquera; Gary A Pestano; Mark A Rubin; Arul M Chinnaiyan; Nallasivam Palanisamy
Journal:  Mod Pathol       Date:  2013-01-25       Impact factor: 7.842

View more
  20 in total

1.  SPINK1 Overexpression in Localized Prostate Cancer: a Rare Event Inversely Associated with ERG Expression and Exclusive of Homozygous PTEN Deletion.

Authors:  Kuo-Cheng Huang; Andrew Evans; Bryan Donnelly; Tarek A Bismar
Journal:  Pathol Oncol Res       Date:  2016-10-13       Impact factor: 3.201

2.  Familial prostate cancer.

Authors:  Veda N Giri; Jennifer L Beebe-Dimmer
Journal:  Semin Oncol       Date:  2016-08-18       Impact factor: 4.929

Review 3.  Histopathology of Prostate Cancer.

Authors:  Peter A Humphrey
Journal:  Cold Spring Harb Perspect Med       Date:  2017-10-03       Impact factor: 6.915

4.  Inherited Predisposition to Prostate Cancer: From Gene Discovery to Clinical Impact.

Authors:  Kathleen A Cooney
Journal:  Trans Am Clin Climatol Assoc       Date:  2017

5.  Germline Mutations in Patients With Early-Onset Prostate Cancer.

Authors:  Tang Tang; Xintao Tan; Ze Wang; Shuo Wang; Yapeng Wang; Jing Xu; Xiajie Wei; Dianzheng Zhang; Qiuli Liu; Jun Jiang
Journal:  Front Oncol       Date:  2022-06-06       Impact factor: 5.738

6.  HOXB13 protein expression in metastatic lesions is a promising marker for prostate origin.

Authors:  Justine Varinot; Adéline Furudoï; Sarah Drouin; Véronique Phe; Raphaele Renard Penna; Morgan Roupret; Marc-Olivier Bitker; Olivier Cussenot; Eva Compérat
Journal:  Virchows Arch       Date:  2016-03-01       Impact factor: 4.064

Review 7.  Prostate cancer SubtyPINg biomarKers and outcome: is clarity emERGing?

Authors:  Steven C Smith; Scott A Tomlins
Journal:  Clin Cancer Res       Date:  2014-06-18       Impact factor: 12.531

8.  Synergistic Interaction of HOXB13 and CIP2A Predisposes to Aggressive Prostate Cancer.

Authors:  Csilla Sipeky; Ping Gao; Qin Zhang; Liang Wang; Otto Ettala; Kirsi M Talala; Teuvo L J Tammela; Anssi Auvinen; Fredrik Wiklund; Gong-Hong Wei; Johanna Schleutker
Journal:  Clin Cancer Res       Date:  2018-09-04       Impact factor: 12.531

Review 9.  The Genomics of Prostate Cancer: A Historic Perspective.

Authors:  Mark A Rubin; Francesca Demichelis
Journal:  Cold Spring Harb Perspect Med       Date:  2019-03-01       Impact factor: 6.915

10.  HOXB13 overexpression is an independent predictor of early PSA recurrence in prostate cancer treated by radical prostatectomy.

Authors:  Cristina Villares Zabalza; Meike Adam; Christoph Burdelski; Waldemar Wilczak; Corina Wittmer; Stefan Kraft; Till Krech; Stefan Steurer; Christina Koop; Claudia Hube-Magg; Markus Graefen; Hans Heinzer; Sarah Minner; Ronald Simon; Guido Sauter; Thorsten Schlomm; Maria Christina Tsourlakis
Journal:  Oncotarget       Date:  2015-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.